Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB161734 in Healthy Male Participants
NCT07814404Phase 1Active, not recruiting
- Sponsor
- Incyte
- Start
- Sep 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of INCB161734, sponsored by Incyte. Primary endpoints: Total Recovery (Urine + Feces) of the Administered Radioactivity up to 2 weeks and Percentage of total radioactive dose in Plasma, Urinary and Fecal Excretion up to 2 weeks. Started Sep 2026; status: active, not recruiting.
02
Drugs
INCB161734
Beyond the preview
Go deeper on NCT07814404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07814404.